WE MAKE AQUACULTURE PROGRESS
PHARMAQ’s New Production Facility Opening in Kløfta, Norway
• Two thousand square meters to produce viral antigens for use in fish vaccines
• State of the art manufacturing facility
• Building on Norwegian biotechnology competence
OSLO, Norway – December 4th, 2017 – PHARMAQ, today announced the opening of a new facility in Kløfta (Norway) for the production of viral antigens for use in fish vaccines. With the establishment of this state of the art facility, PHARMAQ has now the capacity to produce virus antigen for several hundred million vaccine doses annually and will ensure PHARMAQ’s delivery capacity to the international aquaculture industry for the future. The plant received authorization from the Norwegian Medicines Agency on November 1, 2017 and is counting up to twenty five employees.
“Today, we are extremely proud to open this new facility for virus antigen production in Norway” said Morten Nordstad, President PHARMAQ. “Not only this facility will help secure fish vaccines production for the many years to come, but it also represents a real technological step forward in vaccine production for fish. This new site in Kløfta will ensure close cooperation with our R&D organization in Oslo and our production facilities for bacterial antigens and finished vaccines in Overhalla.”
• November 2017 the Norwegian Medicines Agency granted a manufacturer's authorisation to PHARMAQ Virus Manufacturing (PVM) at Kløfta. The authorisation covers the manufacturing of inactivated virus antigens for PHARMAQ's fish vaccines
• 20-25 employees
• 2000 m2, including 400 m2 clean room class B, and 250 m2 quality control laboratories
• Total budget for the project app. 150 MNOK and in cooperation with Oslo Pensjonsforsikring (OPF)
• Enormous capacity – viral antigens for several hundred million vaccine doses
PHARMAQ is the global leader in vaccines and innovation for aquaculture and part of Zoetis, the world leader in animal health. The company provides environmentally sound, safe and efficacious health products to the global aquaculture industry through targeted research and the commitment of dedicated people. Production facilities, administration and research and development activities are based in Norway with subsidiaries in Chile, United Kingdom, China, Vietnam, Turkey, Spain, Panama and Singapore. PHARMAQ has approximately 220 employees and markets products in Europe, North and South America and Asia. For further information, visit the company’s website at www.pharmaq.com
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services. Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in more than 100 countries. In 2016, the company generated annual revenue of $4.9 billion with approximately 9,000 employees. For more information, visit www.zoetis.com.
Did you know...
Newsfeed delivered by Meltwater News. PHARMAQ is not to be held liable for any of its content nor possible incorrect information given.
Entregan detalles de nuevo antiparasitario para combatir el cáligus
I have a gambling problem. I’m not alone.
Market opportunity and growth drivers of Fish vaccine Market till 2024
New sea lice treatment launched in Chile
Pharmaq boosts Chilean presence with parasiticide launch
Pharmaq revela alta efectividad de nuevo antiparasitario contra Caligus
Har en teori om hvorfor mer laks dør av hjerteproblemer
Pharmaq Analytiq utvider staben
Blåbasen skaper ny "marineholme" i Trondheim
Lanzan nuevo antiparasitario que promete control del Caligus